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Ondansetron Versus Metoclopramide in 
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Laparoscopic Cholecystectomy: A Prospective
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OBJECTIVE: Patients who undergo laparoscopic cholecystectomy may be at risk of experiencing post-
operative nausea and vomiting. This prospective, randomized, double-blind study compared the prophylactic
use of metoclopramide and ondansetron for the treatment of postoperative nausea and vomiting in
patients who underwent elective laparoscopic cholecystectomy.
METHODS: Eighty patients were randomized into two groups. Patients received ondansetron 4 mg or
metoclopramide 10 mg intravenously in a double-blind manner at the end of anaesthesia.
RESULTS: The incidence of nausea was 45% for metoclopramide and 20% for ondansetron in the 
24 hours postoperatively; the difference was statistically insignificant (p = 0.05). Postoperative nausea
score did not show any significant difference between the two group in the first 2 hours (p = 0.3) and 
4 hours (p = 0.12) but was significant between 4 and 24 hours (p = 0.02). The incidence of vomiting was
20% for metoclopramide and 2.5% for ondansetron. This difference was statistically significant (p = 0.02).
CONCLUSION: Ondansetron 4 mg given intravenously at the end of surgery is effective for preventing
vomiting after laparoscopic cholecystectomy. [Asian J Surg 2008;31(2):50–4]
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Introduction
Since laparoscopic cholecystectomy (LC) was first perfor-
med in 1987 by Philippe Mouret,1 it has become accepted
as the standard of care in patients with symptomatic
cholelithiasis and has essentially replaced open cholecys-
tectomy for the management of uncomplicated gallblad-
der disease. There is widespread use of this technique around
the world, including in developed and developing countries,
due to the clear advantages of less pain and faster recov-
ery.1 However, postoperative nausea and vomiting (PONV)
are common and distressing complications, and they are
the main concern of 37–72% of patients after laparoscopic
surgery.2–4 Patients reported that their anxiety associated
with PONV was of a greater magnitude than that associated
with postoperative pain5 and were willing to spend up to
US$100 of their own money to avoid this discomfort and
inconvenience.6
Many types of drugs are used for nausea and vomiting.
Commonly used antiemetics include anticholinergic,
antihistamines, butyrophenones and benzamine. Common
side effects such as sedation, dysphoria and extrapyrami-
dal events7 may prolong recovery times. Ondansetron, a
5-hydroxytryptamine subtype 3 (5HT3) receptor antago-
nist, has been documented to be an effective antiemetic in
preventing and treating PONV with few side effects.
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Kyokong et al8 reported that the incidence of PONV in
a placebo group in Thailand was significantly higher than
that in an ondansetron group. The aim of this prospective,
double-blind randomized study was to evaluate the anti-
emetic prophylactic effect of metoclopramide in compar-
ison with ondansetron in patients undergoing elective LC.
Methods
After obtaining informed consent and approval from 
the Chiang Mai Medical Faculty Ethics Committee, 80
consecutive patients, scheduled for elective cholecystec-
tomy, were enrolled into this study. The recruited patients
had an American Society of Anesthesiologist physical 
status of 1 or 2 within an age range of 18–75 years. Exclu-
sion criteria were pregnancy, breast feeding, > 100 kg in
weight, nausea, vomiting or use of antiemetics within 24
hours prior to surgery, insulin-dependent diabetes melli-
tus, conversion to open cholecystectomy, allergy to any
protocol medication and development of intraoperative
complications.
Patients were randomly selected into one of two groups
to receive the study drug at the end of surgery. Random-
ization was performed with sealed envelops containing
the study assignment and kept by the pharmacist who
prepared the drugs. Group 1 received intravenous ondan-
setron 4 mg. Group 2 received intravenous metoclopramide
10 mg. The pharmacy supplied syringes in a blinded fashion
and they were diluted in normal swine serum of equal vol-
ume, so that the patients and the investigator were unaware
of which of the two drugs was being administered.
All patients fasted from midnight before surgery and
premedication with oral midazolam 10 mg was adminis-
tered approximately 1 hour before surgery. Anaesthesia
was delivered in a uniform fashion. Intravenous induction
was performed using thiopentone (5 mg/kg), fentanyl
(1 µg/kg), and endotracheal intubation facilitated by intra-
venous atracurium (0.5 mg/kg). Anaesthesia was main-
tained using 1% isoflurane in 33% oxygen and 67% nitrous
oxide. Intravenous morphine (0.1–0.2 mg/kg) was given
as an analgesic. At the end of surgery, the study drug was
given before reversal of muscle paralysis.
Second generation cephalosporin was the only antibi-
otic that was prescribed before surgery. Standard LC was
performed. The abdominal cavity was inflated with carbon
dioxide at a pressure between 12 and 14 mmHg. Each patient
had a nasogastric tube inserted during the procedure to
decompress the stomach and the tube was removed after
the operation.
Patients were asked to assess their nausea and vomit-
ing at 2, 4 and 24 hours by research nurses who were
blinded to the study. The score at each time point was
based on a 5-point whole number linear scale of 1 = no
nausea, 2 = mild nausea, 3 = moderate nausea, 4 = severe
nausea and 5 = emesis.
A total mean score was used to compare groups.
Patients who reported nausea or vomiting and those who
requested antiemetic therapy or who experienced at least
two episodes of emesis were considered treatment fail-
ures. The choice of rescue antiemetic was left to the dis-
cretion of the doctor. Any adverse events were recorded.
Patients were given feeds when they arrived at the ward
and prescribed postoperative analgesics; intramuscular
diclofenac 75 mg every 6 hours as needed and paraceta-
mol were the only analgesics used for minor pain.
Power analysis was used to determine the number of
patients in the study based on the assumption that: (1)
complete control of PONV would be achieved in 55% of
patients receiving metoclopramide;9 (2) an improvement
in 55–85% would be considered to be of clinical importance;
and (3) α = 0.05 and for a power (1 – β) of 80% based on
these assumptions would require 40 patients per group.
The results from the two treatment groups were com-
pared using the Mann Whitney U test for comparing nausea
and vomiting scores, and the χ2 test for qualitative data.
Results
Eighty patients were randomized into the study with no
patients being removed for protocol violation. Demo-
graphic data were similar in the two groups (Table 1).
PONV data are shown in the Figure. The incidence 
of nausea was 45% for metoclopramide and 20% for
ondansetron (p = 0.05). For emesis, 20% occurred in 
the metoclopramide-treated group and 2.5% in the
ondansetron-treated group (p = 0.02).
Table 2 shows the postoperative nausea score at 2, 4
and 24 hours. The mean postoperative nausea vomiting
score in the ondansetron and metoclopramide group was
1.3 and 1.5 at 2 hours (p = 0.300), 1.1 and 1.5 at 4 hours
(p = 0.122) and 1.0 and 1.5 at 24 hours (p = 0.024), respec-
tively. The total mean score was 3.4 and 4.5, respectively
(p = 0.010). Postoperative nausea score did not show any
significant difference between the two group in the first 
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2 hours (p = 0.3) and 4 hours (p = 0.12) but was significant
between 4 and 24 hours (p = 0.02). No major adverse effects
were observed in the two study groups. Two patients in the
metoclopramide group required rescue antiemetic ther-
apy while none in the ondansetron group did (p = 0.30).
There were no intraoperative and postoperative compli-
cations in the two groups.
Discussion
Regardless of whether or not there are advances in anaes-
thetic agents, the incidence of PONV remains at approxi-
mately 30%10 and multiple factors are associated with the
incidence of PONV. Many factors have been found to
affect postoperative emesis, including patient factors (i.e.
age, gender, obesity, history of motion sickness and/or
previous postoperative nausea, anxiety, gastroparesis),
operative procedures especially after laparoscopy11 and
duration of surgery,12 anaesthetic-related factors (e.g. addi-
tion of nitrous oxide in laparoscopic procedures may
increase the incidence and severity of nausea and vomit-
ing13), and postoperative factors (i.e. pain, dizziness, ambu-
lation, oral intake, use of opioids).14 These factors were
monitored and well balanced between the two groups in
this study, so the actual results should reflect drug effects.
Laparoscopic surgery is associated with a high incidence
of PONV,14 with reported incidence of 40–72%.4,8 The
increase in PONV is becoming recognized as a significant
problem in LC and may be a factor that leads to delay 
in discharging patients from hospital.15 The aetiology of
PONV after laparoscopic surgery performed under general
anaesthesia is not fully understood, but it is probably
multifactorial.14 Several factors, including age, sex, smok-
ing, history of motion sickness, intraoperative use of opi-
oids, residual pneumoperitoneum after CO2 insufflation,16
peritoneal distention, diaphragmatic irritation and visceral
organ irritation and manipulation17 have been considered
to influence the incidence of PONV.
The indiscriminate use of antiemetics is undesirable
as it may prolong anaesthesia or produce unwanted
effects.18 The sedative and extrapyramidal side effects of
antiemetics have driven research in the development of
new agents. Ondansetron, a 5HT3 receptor antagonist, has
been documented to be an effective antiemetic in the pre-
vention of nausea and vomiting associated with patients
receiving chemotherapy or radiotherapy.19
PONV in relation to LC has been studied extensively
in multiple randomized, prospective trials.2–4,8,10,15 These
studies are quite variable in their results, but most of them
found a trend to favour antiemetic drugs for controlling
PONV compared to placebo. One report in Thailand8
studied the role of ondansetron compared to placebo and
Table 1. Baseline data*
Ondansetron (n = 40) Metoclopramide (n = 40) p
Age (yr) 52.45 ± 12.54 52.98 ± 11.01 0.84
Male 10 (25) 13 (32.5) 0.45
Weight (kg) 58.42 ± 11.77 58.93 ± 12.63 0.85
Anaesthetic time (min) 75.25 ± 18.67 78.50 ± 21.46 0.61
Morphine usage during operation (mg) 6.85 ± 1.75 7.05 ± 1.63 0.71
*Data presented as mean ± standard deviation or n (%).
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Figure. Incidence of nausea and vomiting.
Table 2. Postoperative nausea scores
Time (hr) Ondansetron Metoclopramide p
2 1.3 1.5 0.300
4 1.1 1.5 0.122
24 1.0 1.5 0.024
Total 3.4 4.5 0.010
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showed that ondansetron can significantly reduce the inci-
dence of nausea and vomiting. In contrast, other studies
found no significant reduction in PONV using ondansetron
compared to placebo.2,20
Our study compared ondansetron with metoclopramide,
which is extensively used in Thailand because of its lower
price. We showed that ondansetron was more effective in
reducing the incidence of vomiting compared to metoclo-
pramide (2.5% vs. 20%, p = 0.02). The incidence of nausea
in the ondansetron-treated group was also only about 20%
compared to 45% in the metoclopramide-treated group,
but the difference was statistically insignificant (p = 0.05).
The difference in the postoperative nausea score did not
show any significance between the two group in the first
2 hours (p = 0.3) and 4 hours (p = 0.12) but was significant
between 4 and 24 hours (p = 0.02).
Metoclopramide is a central dopaminergic D2 receptor
antagonist and a prokinetic drug that increases gastric
emptying and shortens bowel transit time. The meta-
analysis by Domino et al21 showed that metoclopramide
is not as effective as ondansetron and droperidol in pre-
venting postoperative vomiting. Nesek-Adam et al22 found
that metoclopramide proved to be a poor antiemetic agent
at a dose of 10 mg and was associated with a high incidence
of PONV (45%). Metoclopramide has a short half-life,
which is probably why our study showed that there was
no significant difference in PONV in the first 4 hours
postoperatively compared to ondansetron.
Although many physicians may view PONV as a minor
irritation, Kovac et al23 reported that 38% of patients who
experience PONV perceive it to be as or more debilitating
than the after effects of surgery itself.
In summary, ondansetron given at the end of anaes-
thesia was more effective in decreasing the incidence of
PONV in patients undergoing elective LC compared with
metoclopramide. Intravenous ondansetron at the end of
anaesthesia should become the standard for all patients
undergoing LC, even though it is more expensive.
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